CClinicalTrials.gg
RecruitingNCT07596147SAFE-EFFECTUpdated May 19, 2026

SAFE Early Intervention for At-Risk Infants

An interventional study of SAFE Early Intervention Program and NDT TREATMENT in High Risk Infant, Neurodevelopmental Disorder (Diagnosis) and Preterm, sponsored by Gazi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 3 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Gazi University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
3 Months to 12 Months
Sex
All
01

Study summary

This randomized controlled study aims to investigate the effects of the SAFE early intervention approach on upper extremity function, fine motor skills, and developmental outcomes in high-risk infants aged 3-12 months. Thirty high-risk infants admitted to the Developmental Physiotherapy and Pediatric Rehabilitation Unit of Gazi University Faculty of Health Sciences will be randomly assigned to either the SAFE early intervention group or the Neurodevelopmental Treatment (NDT) group.

Infants in the intervention group will receive the SAFE early intervention program for 8 weeks under the supervision of an experienced pediatric physiotherapist. The SAFE approach includes age-appropriate activities focusing on environmental enrichment, promotion of voluntary and goal-directed movements, sensory stimulation, fine motor skill development, postural control, transitional movements, and enhancement of infant-parent interaction through daily routines and home-based activities.

Infants in the control group will receive conventional Neurodevelopmental Treatment (NDT) for 8 weeks. The NDT program includes age-specific activities targeting postural control, muscle tone regulation, facilitation of motor development, hand function, balance, weight transfer, and fine motor skills.

Families will receive education regarding home-based activities and facilitation techniques specific to their infant's developmental needs. Follow-up will include home visits and weekly telephone monitoring to ensure adherence to the intervention program. Assessments will be performed before the intervention and after the 8-week intervention period by a physiotherapist blinded to group allocation.

Read the detailed description

This randomized controlled study investigates the effects of two different early intervention approaches in high-risk infants. The SAFE intervention program is compared with conventional Neurodevelopmental Treatment (NDT). Assessments include upper extremity function, fine motor development, and developmental outcomes measured at baseline and follow-up periods. The study aims to determine which intervention provides superior improvement in early motor and developmental skills.

02

Conditions studied

  • High Risk Infant
  • Neurodevelopmental Disorder (Diagnosis)
  • Preterm

Keywords

  • early intervention
  • high risk infant
  • upper limb function
03

Who can participate

Ages eligible
3 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Infants aged between 3 and 12 months corrected age Presence of neurodevelopmental risk factors including perinatal stroke, perinatal asphyxia, hypoxic-ischemic encephalopathy, germinal matrix hemorrhage, intraventricular hemorrhage, periventricular leukomalacia, or prematurity at or below 37 weeks of gestation Admission to the Developmental Pediatrics and Pediatric Physiotherapy and Rehabilitation Unit of Gazi University Faculty of Health Sciences Parent or legal guardian willing to participate and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Presence of any congenital anomaly Diagnosis of a genetic disorder Any orthopedic problem affecting upper extremity function Families unable to communicate in Turki
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    SAFE EARLY İNTERVENTION group

    SAFE-based early intervention for high-risk infants: The SAFE early intervention approach will be implemented to improve proximal stabilisation in high-risk infants aged between 3 and 12 months.

    Behavioral: SAFE Early Intervention Program

  • Active comparator
    NDT TREATMENT GROUP

    Neurodevelopmental Treatment (NDT): The NDT approach, which aims to develop fine motor skills in high-risk infants aged between 3 and 12 months, will be implemented

    Behavioral: NDT TREATMENT

Interventions

  • BehavioralSAFE Early Intervention Program

    Structured early intervention program designed for high-risk infants focusing on upper extremity function, fine motor development, and neurodevelopmental outcomes during 8 weeks, 5 days/week

  • BehavioralNDT TREATMENT

    Conventional neurodevelopmental treatment approach focusing on postural control, motor development, and functional movement patterns during 8 weeks, 5days/week

05

What researchers measure

Primary outcomes

  1. Hand Assessment for Infants (HAI)

    he Hand Assessment for Infants (HAI) will be used to evaluate upper extremity and hand function in high-risk infants through observational video analysis. The assessment includes reaching, grasping, object manipulation, bilateral hand use, and spontaneous hand movements during structured play activities.

    Time frame: Baseline and after 8 weeks of intervention

  2. Peabody Developmental Motor Scales - Second Edition (PDMS-2)

    The Peabody Developmental Motor Scales - Second Edition (PDMS-2) will be used to assess gross and fine motor development in high-risk infants aged 3-12 months. The assessment includes reflexes, stationary skills, locomotion, object manipulation, grasping, and visual-motor integration. Higher scores indicate better motor performance and developmental function.

    Time frame: Baseline and after 8 weeks of intervention

Secondary outcomes

  1. Canadian Occupational Performance Measure (COPM)

    The Canadian Occupational Performance Measure (COPM) will be used to evaluate parent-perceived performance and satisfaction related to the infant's functional goals. Parents will identify important activity-related goals and rate performance and satisfaction using a 10-point scale. Higher scores indicate better occupational performance and greater parental satisfaction.

    Time frame: Baseline and after 8 weeks of intervention

  2. PedsQL™ Infant Quality of Life Scale (1-12 Months)

    The PedsQL™ Infant Quality of Life Scale will be used to assess health-related quality of life in infants based on parent report. The scale evaluates physical functioning, emotional status, social interaction, and general well-being. Higher scores indicate better quality of life.

    Time frame: Baseline and after 8 weeks of intervention

06

Study locations

1 of 1 sites recruiting
  • Gazi University Faculty of Health Sciences
    Ankara, Ankara 06490, Turkey (Türkiye)
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07596147
Lead sponsor
Gazi University
Responsible party
Ecem Yildiz CANGUR (Research Assistant, Gazi University) — Principal investigator
First posted
May 19, 2026
Start date
Feb 16, 2026
Primary completion
Jun 16, 2026 (estimated)
Completion
Jul 16, 2026 (estimated)
Last update
May 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion